ACAD analyst estimates

Acadia Pharmaceuticals (ACAD) analyst ratings, the average price target and its range, and every firm's latest call.

ACAD analyst ratings and price targets

DateFirmCallTarget
Oct 13, 2026UBSAcadia Pharmaceuticals downgraded to Neutral from Buy at UBS$23.00
Sep 28, 2026William BlairAcadia Pharmaceuticals (ACAD) PT Lowered to $33 at H.C. Wainwright$33.00
Sep 25, 2026NeedhamAcadia Pharmaceuticals (ACAD) PT Lowered to $35 at Needham$35.00
Sep 25, 2026BMO CapitalAcadia Pharmaceuticals price target lowered to $34 from $36 at BMO Capital$34.00
Sep 25, 2026Deutsche BankAcadia Pharmaceuticals price target lowered to $31 from $38 at Deutsche Bank$31.00
Sep 25, 2026H.C. WainwrightAcadia price target lowered to $33 from $37 at H.C. Wainwright$33.00
Aug 25, 2026Morgan StanleyAcadia Pharmaceuticals price target raised to $28 from $27 at Morgan Stanley$28.00
Aug 25, 2026Deutsche BankAcadia Pharmaceuticals price target raised to $38 from $37 at Deutsche Bank$38.00
Aug 17, 2026UBSAcadia Pharmaceuticals price target raised to $49 from $45 at UBS$49.00
Aug 12, 2026NeedhamAcadia Pharmaceuticals price target raised to $41 from $38 at Needham$41.00
Aug 10, 2026Morgan StanleyAcadia Pharmaceuticals price target raised to $27 from $26 at Morgan Stanley$27.00
Aug 5, 2026OppenheimerAcadia Pharmaceuticals (ACAD) PT Raised to $25 at Oppenheimer$25.00
Aug 5, 2026RBC CapitalAcadia Pharmaceuticals (ACAD) PT Raised to $37 at RBC Capital on 'Strong Sales'$37.00
Jul 29, 2026Raymond JamesAcadia Pharmaceuticals (ACAD) PT Raised to $14.50 at BofA Securities$14.50
Jul 21, 2026BMO CapitalAcadia Pharmaceuticals price target raised to $36 from $34 at BMO Capital$36.00

Updated 2026-11-02 23:10 UTC